Words similar to ifnγ
Example sentences for: ifnγ
How can you use “ifnγ” in a sentence? Here are some example sentences to help you improve your vocabulary:
Of the various cytokines tested (TNFα, IFNγ, or sFasL), TNFα was the only potent initiator of CLENDO cell death.
Indeed, tumor necrosis factor α (TNFα), interferon gamma (IFNγ) and/or interleukin-1 beta (IL-1β) have all been shown to reduce gonadotrophin-induced progesterone synthesis in a number of species [ 8 9 10 11 12 ] , and TNFα and IFNγ are known to increase PGF 2α production by steroidogenic cells [ 13 14 15 ] . Steroidogenic cell apoptotic paradigms are activated by cytokines generated by several cell types within the CL, including immune cells and endothelial cells [ 7 11 16 ] . The synergistic actions of IFNγ and TNFα, for example, induce steroidogenic cell apoptosis [ 13 17 ] , as does soluble Fas ligand (FasL) [ 18 19 20 21 22 23 24 25 26 ] . Furthermore, several acute intracellular signaling events either required for, or associated with, the functional and structural aspects of luteal regression have been mapped using in vitro steroidogenic cell cultures [ 8 27 28 ] .
SLC/CCL21 is documented to have direct anti-angiogenic effects [ 28 29 ] ; the tumor reductions observed in this model could have been due to participation by T cells secreting IFNγ leading to inhibition of angiogenesis via MIG/CXCL9 and IP-10/CXCL10, as well as T cell-dependent immunity [ 16 ] . IFNγ mediates a range of biological effects that facilitate anticancer immunity.
TNFα treatment resulted in a significant reduction in CLENDO cell viability (34 %, P < 0.05), which was reduced (P < 0.05) an additional 23 % by co-treatment with IFNγ (Fig.
Compared to SLC/CCL21-treated mice receiving control antibody, flow cytometric evaluation of single-cell suspensions of non-necrotic tumors from SLC/CCL21-treated mice receiving neutralizing antibodies to MIG/CXCL9, IP-10/CXCL10 and IFNγ showed 10, 12 and 31 % decreases, respectively, in the gated CD3 CXCR3 +veT cell populations (Table 1).
Loading...